Navigation Links
China-Biotics, Inc. Appoints New Vice President
Date:10/30/2009

SHANGHAI, Oct. 30 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced the appointment of Dr. Tom Gu as Vice President, effective November 2. In this role, Dr. Gu will oversee the development of China Biotics' probiotics products in order to meet the growing demand the Company has seen from China and the global market.

Dr. Gu has an impressive background in biochemistry and pathology with extensive practical experience in U.S. FDA-certified medical applications obtained from his work at China-based medical companies over the past eight years. Previously, Dr. Gu served as project manager for Life Technologies Corporation in the United States. Dr. Gu graduated from the University of Arizona with a Ph.D in molecular medicine. He received an EMBA from North Virginia University and a Bachelor of Science degree in biochemistry from Jilin University of China. Dr. Gu has also conducted postdoctoral research with the National Institutes of Health and previously served as a director of the United States Federation for Culture Collections. In addition, Dr. Gu is currently a member of the Expert Committee of the Shanghai Zhangjiang Bio-Pharmaceutical Base.

"We are very excited to have someone of Dr. Gu's caliber join us and lead our research and development team," said Mr. Jinan Song, Chairman and Chief Executive Officer of China Biotics. "His impressive academic achievements and practical experience will enhance and solidify our R&D capabilities, which will be of critical importance as we expand the scale of our operations. We are currently in trial production at our new 150 metric ton probiotics facility, which we expect to complete by year end. At that point, we will begin the second phase of our capacity expansion. Dr. Gu's education and practical experience in United States will be an asset in evaluating and assessing potential overseas business opportunities."

"I'm delighted to have the opportunity to join a company with such a strong reputation for innovation and quality as China-Biotics. I look forward to sharing my knowledge and experience in order to help China-Biotics further extend its reach and reputation as a leading probiotics company," said Dr. Gu.

About China-Biotics, Inc.

China-Biotics, Inc., a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

     Eva Yan, CFO
     Email: evayan@chn-biotics.com
     Web:   http://www.chn-biotics.com

     CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China-Biotics, Inc.


'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit
2. China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results
3. China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
4. China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations
5. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results
6. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
7. China-Biotics, Inc. to Join Russell 3000 Index
8. China-Biotics, Inc. to Attend Digestive Disease Week 2009
9. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
10. China-Biotics, Inc. Supplies Probiotics as Additive for Poultry Feed
11. China-Biotics, Inc. Appoints New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseqâ„¢ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
Breaking Biology Technology:
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
(Date:2/21/2017)... and PORTLAND, Ore. , ... and the Avamere Family of Companies (Avamere Health Services, ... announced a six-month research study that will apply the ... eldercare at senior living and health centers. By analyzing ... hopes to gain insights into physical and environmental conditions, ...
Breaking Biology News(10 mins):